Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Exclusion Criteria

• •1. History of or current clinically significant medical illness or any other illness that in the opinion of the investigator interferes with the interpretation of the study results
• •2. Clinically significant abnormal physical examination, vital signs, or clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening as determined by the investigator
• •3. Previous receipt of any cytomegalovirus vaccine
• •4. History of allergic reactions or anaphylactic reaction to any vaccine component
• •5. Pregnant or breastfeeding or plans to conceive from two weeks before the study start through six months after the last dose of study vaccine
• •6. Known or suspected impairment of immunological function, including but not limited to autoimmune diseases, splenectomy, or HIV/AIDS
• •7. Chronic administration (defined as more than 14 days in total) of immune-suppressive or other immune-modifying drug with six months prior to the product dose (for corticosteroids, this is defined as prednisone ≥20 mg/day or equivalent). Inhaled and topical steroids are allowed
• •8. Participation in another clinical study within 30 days or plans to participate in another treatment based clinical study during the conduct of the present study
• •9. Any skin abnormality or tattoo that would limit post-vaccination injection site assessment
• •10. Any history of cancer requiring chemotherapy or radiation within 5 years of randomization or current disease
• •11. Are family members of study center staff